Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $3.2 million.

  • Cartesian Therapeutics' Prepaid Assets fell 2361.35% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 2361.35%. This contributed to the annual value of $3.1 million for FY2024, which is 3670.22% down from last year.
  • Cartesian Therapeutics' Prepaid Assets amounted to $3.2 million in Q3 2025, which was down 2361.35% from $2.7 million recorded in Q2 2025.
  • Cartesian Therapeutics' Prepaid Assets' 5-year high stood at $8.2 million during Q2 2021, with a 5-year trough of $2.0 million in Q2 2024.
  • Over the past 5 years, Cartesian Therapeutics' median Prepaid Assets value was $4.1 million (recorded in 2024), while the average stood at $4.6 million.
  • As far as peak fluctuations go, Cartesian Therapeutics' Prepaid Assets skyrocketed by 68639.85% in 2021, and later crashed by 5199.62% in 2024.
  • Cartesian Therapeutics' Prepaid Assets (Quarter) stood at $6.5 million in 2021, then plummeted by 41.64% to $3.8 million in 2022, then soared by 31.47% to $5.0 million in 2023, then plummeted by 36.7% to $3.1 million in 2024, then rose by 0.32% to $3.2 million in 2025.
  • Its Prepaid Assets was $3.2 million in Q3 2025, compared to $2.7 million in Q2 2025 and $2.9 million in Q1 2025.